Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 2
1996 2
1997 1
1998 3
2002 1
2005 1
2007 1
2009 1
2010 3
2011 8
2012 2
2013 3
2014 1
2017 7
2018 8
2019 2
2020 1
2021 3
2022 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Xiao S, Chan P, Wang T, Hong Z, Wang S, Kuang W, He J, Pan X, Zhou Y, Ji Y, Wang L, Cheng Y, Peng Y, Ye Q, Wang X, Wu Y, Qu Q, Chen S, Li S, Chen W, Xu J, Peng D, Zhao Z, Li Y, Zhang J, Du Y, Chen W, Fan D, Yan Y, Liu X, Zhang W, Luo B, Wu W, Shen L, Liu C, Mao P, Wang Q, Zhao Q, Guo Q, Zhou Y, Li Y, Jiang L, Ren W, Ouyang Y, Wang Y, Liu S, Jia J, Zhang N, Liu Z, He R, Feng T, Lu W, Tang H, Gao P, Zhang Y, Chen L, Wang L, Yin Y, Xu Q, Xiao J, Cong L, Cheng X, Zhang H, Gao D, Xia M, Lian T, Peng G, Zhang X, Jiao B, Hu H, Chen X, Guan Y, Cui R, Huang Q, Xin X, Chen H, Ding Y, Zhang J, Feng T, Cantillon M, Chen K, Cummings JL, Ding J, Geng M, Zhang Z. Xiao S, et al. Among authors: cantillon m. Alzheimers Res Ther. 2021 Mar 17;13(1):62. doi: 10.1186/s13195-021-00795-7. Alzheimers Res Ther. 2021. PMID: 33731209 Free PMC article. Clinical Trial.
Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials.
Mortby ME, Adler L, Agüera-Ortiz L, Bateman DR, Brodaty H, Cantillon M, Geda YE, Ismail Z, Lanctôt KL, Marshall GA, Padala PR, Politis A, Rosenberg PB, Siarkos K, Sultzer DL, Theleritis C; ISTAART NPS PIA. Mortby ME, et al. Among authors: cantillon m. Am J Geriatr Psychiatry. 2022 Feb;30(2):119-147. doi: 10.1016/j.jagp.2021.06.016. Epub 2021 Jul 1. Am J Geriatr Psychiatry. 2022. PMID: 34315645 Free article. Review.
Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial.
Jost ST, Aloui S, Evans J, Ashkan K, Sauerbier A, Rizos A, Petry-Schmelzer JN, Gronostay A, Fink GR, Visser-Vandewalle V, Antonini A, Silverdale M, Timmermann L, Martinez-Martin P, Chaudhuri KR, Dafsari HS; International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group and EUROPAR. Jost ST, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2352177. doi: 10.1001/jamanetworkopen.2023.52177. JAMA Netw Open. 2024. PMID: 38236600 Free PMC article. Clinical Trial.
Mechanisms underlying resilience in ageing.
Stern Y, Chételat G, Habeck C, Arenaza-Urquijo EM, Vemuri P, Estanga A, Bartrés-Faz D, Cantillon M, Clouston SAP, Elman JA, Gold BT, Jones R, Kempermann G, Lim YY, van Loenhoud A, Martínez-Lage P, Morbelli S, Okonkwo O, Ossenkoppele R, Pettigrew C, Rosen AC, Scarmeas N, Soldan A, Udeh-Momoh C, Valenzuela M, Vuoksimaa E. Stern Y, et al. Among authors: cantillon m. Nat Rev Neurosci. 2019 Apr;20(4):246. doi: 10.1038/s41583-019-0138-0. Nat Rev Neurosci. 2019. PMID: 30814677 No abstract available.
Biomarkers for Alzheimer's disease therapeutic trials.
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group. Hampel H, et al. Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2. Prog Neurobiol. 2011. PMID: 21130138 Review.
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria.
Ismail Z, Gatchel J, Bateman DR, Barcelos-Ferreira R, Cantillon M, Jaeger J, Donovan NJ, Mortby ME. Ismail Z, et al. Among authors: cantillon m. Int Psychogeriatr. 2018 Feb;30(2):185-196. doi: 10.1017/S1041610217001880. Epub 2017 Sep 13. Int Psychogeriatr. 2018. PMID: 28899446 Free article. Review.
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.
Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. Boxer AL, et al. Among authors: cantillon m. Alzheimers Dement. 2013 Mar;9(2):176-88. doi: 10.1016/j.jalz.2012.03.002. Epub 2012 Oct 5. Alzheimers Dement. 2013. PMID: 23043900 Free PMC article. Review.
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).
Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. Boxer AL, et al. Among authors: cantillon m. Alzheimers Dement. 2013 Mar;9(2):189-98. doi: 10.1016/j.jalz.2012.03.003. Epub 2012 Oct 10. Alzheimers Dement. 2013. PMID: 23062850 Free PMC article. Review.
47 results